Race to Save Humanity: Inside $12B Colossal Biosciences & $3.8B Astromech

Biodiversity Crisis & Mission Scope:

• Current forecasts predict the loss of up to 50% of global biodiversity within the next 25 years.
• Colossal positions itself not as a replacement for modern conservation, but as a "de-extinction toolkit" to provide a backup plan for species loss.
• The company intends to open-source its technologies for free use by the conservation community to mitigate ecosystem collapse.
• Ben Lamb (CEO) describes the company's trajectory as a "digital twin of nature," utilizing AI to model real-time consequences of human decisions on ecosystems.

Woolly Mouse Breakthrough & Metrics:

• The team successfully generated 100% healthy woolly mice with predicted phenotypes using the most multiplexed edits delivered simultaneously ever recorded.
• The entire gestation and editing process for the first generation took only 30 days.
• The mice serve as a functional model for testing core phenotypes relevant to the woolly mammoth project, bypassing the 22-month elephant gestation timeline.
• Over 635 million dollars in total capital has been raised, with the most recent round being over-subscribed (targeting $200M, raising $400M).

Technology & "Civilization Tech":

• Colossal views its work as "civilization tech," a category beyond "moonshots" with broad applications for humanity, including biocontrol, healthcare, and material production.
• The company spun out a subsidiary, Astromech, which uses AI to analyze evolutionary trends (e.g., cancer suppression in elephants via p53 proteins) to develop focused drug discovery models without massive data center requirements.
• Invasive species (e.g., screw worm in Texas, ticks in the Northeast) are identified as a $500 billion global problem solvable via gene drives, which could eradicate populations in 6–7 months compared to decades for traditional methods.
• The company is developing lab-grown hair follicles (specifically mammoth hair) for ethical textile production, addressing supply chains where demand exceeds available wild animal populations by 5x–6x.

Operational Scale & Vertical Integration:

• The facility spans 55,000 square feet of office space plus 30,000 square feet of lab space, including an 8,000-square-foot vivarium.
• Colossal acquired Biogen's US cloning arm to secure high-efficiency cloning capabilities (up to 80% vs. industry standard 2%) for vertical integration.
• The organization employs over 260 staff, 17 academic partners, 80 external academic lab researchers, and 95 advisors, including a dedicated youth advisory board.
• Internal processes have shifted from traditional academic isolation to software-driven efficiency, using Jira, AI-driven computer vision for lab automation, and real-time data aggregation to track cloning rates and efficiencies.

Ethical Boundaries & Public Engagement:

• No-Go List: The company explicitly refuses to work on human genome editing, non-human primates, or giant prehistoric apes (e.g., Gigantopithecus).
• Speculative Requests: The team fields frequent requests regarding Megalodon, dinosaurs, and UAP (UFO) mashups, which they categorically deny pursuing due to lack of DNA and ethical constraints.
• Public Perception: The office features animatronic dire wolves and digital projections to manage public curiosity, as actual extinct species are not yet housed on-site.
• Controversy: Colossal acknowledges early friction with the conservation community, which initially viewed de-extinction as a distraction from modern conservation efforts.

Future Outlook (12 Months):

• The company anticipates the birth of its first extinct species (likely a bird or mammoth) within the next 12 months.
• Future goals involve releasing engineered species or gene drives into the wild only after securing government, indigenous, and private landowner support.
• Lamb emphasizes a "Harvard meets MTV" branding strategy to make science appealing to youth, arguing that inspiration and value creation are equally critical for long-term success.